Editorial: Hepatocellular carcinoma in type 2 diabetes: More than meets the eye

American Journal of Gastroenterology

Volumn 107, Issue 1, 2012, Pages 53-55

  Baffy, György ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; METFORMIN;

CANCER RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION;

CARCINOMA, HEPATOCELLULAR; DIABETES COMPLICATIONS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIVER NEOPLASMS; MALE;

EID: 84855430962     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.390     Document Type: Review

References (24)

1. Bosch FX, Ribes J, Cleries R et al. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9: 191-211, v.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76. (Pubitemid 46890874)
3. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-91.
4. Charlton M. Cirrhosis and liver failure in nonalcoholic fatty liver disease: Molehill or mountain? Hepatology 2008; 47: 1431-3. (Pubitemid 351702725)
5. Calle EE, Rodriguez C, Walker-Th urmond K et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003; 348: 1625-38. (Pubitemid 36459468)
6. Wideroff L, Gridley G, Mellemkjaer L et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997; 89: 1360-5. (Pubitemid 27418027)
7. Adami HO, Chow WH, Nyren O et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 1996; 88: 1472-7. (Pubitemid 26340049)
8. Davila JA, Morgan RO, Shaib Y et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54: 533-9. (Pubitemid 40403031)
9. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4: 369-80. (Pubitemid 43343895)
10. Lai S-W, Chen P-C, Liao K-F et al. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a popu lationbased cohort study. Am J Gastroenterol 2012;107:46-52 (this issue).
11. Shoelson SE, Herrero L, Naaz A. Obesity, infl ammation, and insulin resistance. Gastroenterology 2007; 132: 2169-80. (Pubitemid 46693756)
12. Hotamisligil GS. Infl ammation and metabolic disorders. Nature 2006; 444: 860-7.
13. Ekstedt M, Franzen LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-73. (Pubitemid 46489550)
14. Adams LA, Lymp JF, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-21. (Pubitemid 41002048)
15. Adams LA, Sanderson S, Lindor KD et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42: 132-8. (Pubitemid 40038911)
16. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
17. Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinico-histopathologic study of 804 North American patients. Am J Clin Pathol 1996; 105: 65-75.
18. Brancatelli G, Federle MP, Grazioli L, et al. Hepatocellular carcinoma in noncirrhotic liver: CT, clinical, and pathologic findings in 39 US residents. Radiology 2002; 222: 89-94. (Pubitemid 34031471)
19. Sanyal A, Poklepovic A, Moyneur E et al. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 2010; 26: 2183-91.
20. Caldwell SH, Oelsner DH, Iezzoni JC et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-9. (Pubitemid 29109578)
21. Marrero JA, Fontana RJ, Su GL et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36: 1349-54. (Pubitemid 35403524)
22. Williams CD, Stengel J, Asike MI et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-31.
23. Giovannucci E, Harlan DM, Archer MC et al. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33: 1674-85.
24. Stickel F, Hellerbrand C. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut 2010; 59: 1303-7.